Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover speculation, a spokesman for the Swiss drugmaker said on Thursday. "We have no intention to pursue them," spokesman Eric Althoff said in response to inquiries.The Wall Street Journal earlier reported that Novartis - which operates a large generics business called Sandoz - was considering whether to enter the fray, after Actavis rebuffed separate takeover offers from Valeant Pharmaceuticals International Inc and Mylan Inc.
Mylan, Inc. develops and markets generics along with a number of proprietary drugs. Shares of MYL remained unchanged at $30.50. In the past year, the shares have traded as low as $20.21 and as high as $31.22. On average, 5733330 shares of MYL exchange hands on a given day and today's volume is recorded at 0.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX remained unchanged at $76.33. In the past year, the shares have traded as low as $42.47 and as high as $77.44. On average, 1417170 shares of VRX exchange hands on a given day and today's volume is recorded at 0.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 1.2% or $-0.94/share to $77.64. In the past year, the shares have traded as low as $43.99 and as high as $77.70. On average, 418769 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 0.
Source
